

# National Board of Examinations

<b>Question Paper Name :</b>	DrNB Medical Oncology Paper3
<b>Subject Name :</b>	DrNB Medical Oncology Paper3
<b>Creation Date :</b>	2022-12-26 13:13:25
<b>Duration :</b>	180
<b>Share Answer Key With Delivery Engine :</b>	No
<b>Actual Answer Key :</b>	No

## DrNB Medical Oncology Paper3

<b>Group Number :</b>	1
<b>Group Id :</b>	3271871324
<b>Group Maximum Duration :</b>	0
<b>Group Minimum Duration :</b>	180
<b>Show Attended Group? :</b>	No
<b>Edit Attended Group? :</b>	No
<b>Group Marks :</b>	100
<b>Is this Group for Examiner? :</b>	No
<b>Examiner permission :</b>	Cant View
<b>Show Progress Bar? :</b>	No

## DrNB Medical Oncology Paper3

<b>Section Id :</b>	3271871327
<b>Section Number :</b>	1
<b>Section type :</b>	Offline

<b>Mandatory or Optional :</b>	Mandatory
<b>Number of Questions to be attempted :</b>	10
<b>Section Marks :</b>	100
<b>Enable Mark as Answered Mark for Review and Clear Response :</b>	Yes
<b>Maximum Instruction Time :</b>	0
<b>Sub-Section Number :</b>	1
<b>Sub-Section Id :</b>	3271871331
<b>Question Shuffling Allowed :</b>	No
<b>Is Section Default? :</b>	null

**Question Number : 1 Question Id : 32718712292 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0**

**Correct Marks : 10**

**Please write your answers in the answer booklet within the allotted pages as follows:-**

Question Number	Answer to be attempted within	Question Number	Answer to be attempted within
Q. 1	Page 1-5	Q. 6	Page 26-30
Q. 2	Page 6-10	Q. 7	Page 31-35
Q. 3	Page 11-15	Q. 8	Page 36-40
Q. 4	Page 16-20	Q. 9	Page 41-45
Q. 5	Page 21-25	Q. 10	Page 46-50

1.a) Define cisplatin ineligibility in relation to head and neck cancer and discuss other treatment options for concurrent chemotherapy in ineligible patients. [5]

b) Discuss the re-irradiation in recurrent squamous cell carcinoma of head and neck. [5]

**Question Number : 2 Question Id : 32718712293 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0**

**Correct Marks : 10**

a) Discuss the molecular genetics of Chronic Myeloid Leukaemia. [4]

b) Discuss the initial management and response monitoring for a new patient of Chronic Myeloid

Leukaemia started on TKI. [6]

**Question Number : 3 Question Id : 32718712294 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0**

**Correct Marks : 10**

- a) Define the criteria for unresectability in locally advanced Pancreatic Cancer. [3]
- b) Discuss the approach to initial systemic therapy for metastatic Pancreatic Cancer. [4]
- c) Discuss adjuvant therapy in resected pancreatic ductal adenocarcinoma. [3]

**Question Number : 4 Question Id : 32718712295 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0**

**Correct Marks : 10**

- a) Discuss the various mutations seen in GIST and the first and second line therapies in metastatic GIST. [5]
- b) Briefly discuss common hereditary syndrome in colon cancers. [5]

**Question Number : 5 Question Id : 32718712296 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0**

**Correct Marks : 10**

- a) Discuss selective bladder preservation approaches in non-metastatic muscle invasive bladder cancer. [5]
- b) Discuss the treatment related sequelae in testicular cancer survivors. [5]

**Question Number : 6 Question Id : 32718712297 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0**

**Correct Marks : 10**

- a) Discuss the approach to first line therapy for ER positive HER 2 positive metastatic breast

cancer. [5]

b) Discuss the benefits of dose dense chemotherapy versus routine chemotherapy for adjuvant breast cancer. [5]

**Question Number : 7 Question Id : 32718712298 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0**

**Correct Marks : 10**

a) Discuss the evidence for adjuvant chemotherapy for soft tissue sarcomas. [5]

b) Discuss the approach to first line therapy for metastatic cutaneous melanoma. [5]

**Question Number : 8 Question Id : 32718712299 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0**

**Correct Marks : 10**

a) Lymphoplasmacytic lymphoma. [5]

b) Current diagnostic criteria for multiple myeloma. [5]

**Question Number : 9 Question Id : 32718712300 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0**

**Correct Marks : 10**

a) Discuss the complications seen during induction therapy for ALL. [5]

b) Discuss the clinical features and risk stratification of Medulloblastoma in children. [5]

**Question Number : 10 Question Id : 32718712301 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0**

**Correct Marks : 10**

a) Latest trends in decreasing the cost of cancer care with low dose therapies. [5]

b) Sexual problems in women with cancer. [5]